Abstract
Checkpoint inhibition by anti-PD-1 antibodies alone or in combination with CTLA-4 blockers is the new paradigm in the treatment of metastatic melanoma (1,2). Response rates are high with about 40% in anti-PD-1 monotherapy and about 60% in combination with anti-CTLA-4 inhibitors (3). Initially, responses were assumed to be durable, but soon it became evident that even deeply responding patients with completely decreased metastases bear the potential to relapse even under continuously ongoing therapy (4,5). The molecular mechanisms of this acquired resistance remained unclear until now, when Zaretsky and coworkers from the group of Antoni Ribas succeeded to unravel some first molecular mechanisms helping to understand this complex clinical situation (6).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.